Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Key findings of the pooled analysis of the TOURMALINE-MM3 and MM4 trials

Bruno Paiva • 25 Aug 2022
IMS 2022
Multiple Myeloma Ixazomib
TOURMALINE-MM3 TOURMALINE-MM4

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the results from a pooled analysis of the TOURMALINE-MM3 (NCT02181413) and TOURMALINE-MM4 (NCT02312258) studies, which are investigating measurable residual disease (MRD) dynamics during maintenance therapy with ixazomib versus placebo in transplant-eligible and ineligible myeloma patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bruno Paiva

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
2:08
Minimally invasive assessment of MRD in multiple myeloma
Bruno Paiva • 9 Dec 2023
2:34
Mutant hematopoietic progenitor cells in MM associated with secondary primary malignancies
Bruno Paiva • 9 Dec 2023
1:52
Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers
Bruno Paiva • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals